Breaking News

Ambrx Appoints CEO

January 7, 2013

Macartney brings 20 years of pharma experience

Lawson Macartney, Ph.D., DVM, has been appointed president and chief executive officer of Ambrx, and a member of the board of directors. Dr. Macartney has more than 20 years of experience in the pharma industry. Most recently, he served as senior vice president and head of the emerging business unit at Shire Pharmaceuticals, where he contributed to growing and diversifying the clinical pipeline.
Prior to joining Shire in 2011, Mr. Macartney was senior vice president of global product strategy and project/portfolio management for GlaxoSmithKline, where he spent four years overseeing the commercial evaluation and commercial strategy for assets at all stages of development and identifying in-licensing opportunities. He held additional positions at GlaxoSmithKline, Astra Pharmaceuticals and Ribozyme Pharmaceuticals.
"We are excited to have Lawson lead Ambrx as our pipeline of therapeutics, including our drug conjugates, continues to grow and mature," said John Diekman, Ph.D., chairman of Ambrx's board of directors. "Ambrx has demonstrated the strength of its technology base and pipeline through data and collaborations, and now we believe Lawson's expertise positions him to lead the company in the next stage of its growth."
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.